Stem Cells Show Promising Results in Treating Severe COVID-19 Symptoms

Since the onset of the COVID-19 pandemic in 2020, our research team promptly initiated an emergency project to study the use of stem cell therapy in treating COVID-19. This project included the development of the world's first stem cell drug approved for clinical trials to treat COVID-19 and the rigorous testing and clinical research of mesenchymal stem cell preparations.

Our research team, consisting of top stem cell experts, conducted extensive preclinical research and quality assessments. This solid foundation enabled us to quickly move into clinical studies, demonstrating the safety and effectiveness of stem cell therapy. Early clinical trials in Wuhan involved 64 critically ill patients. Results showed that stem cell treatment was both safe and effective, with significant improvements in respiratory distress and overall clinical outcomes. Patients generally reached recovery within 8 to 10 days.

Stem cells have shown unique advantages in preventing and repairing lung fibrosis, which is crucial for the long-term recovery of COVID-19 patients. Since the pandemic began, we have treated over 500 critically ill patients. Globally, more than 2,000 clinical observational studies on stem cells and immune cell therapy for COVID-19 have been conducted. In 2021, Japan approved a stem cell drug specifically for treating COVID-19 sequelae, further proving the therapeutic value of cellular treatments.

NK Cells Play a Vital Role in COVID-19 Prevention and Treatment

Natural Killer (NK) cells have also demonstrated remarkable potential in combating COVID-19. Studies suggest that NK cell therapy, derived from autologous peripheral blood, is safe, effective, and convenient for preventing and treating SARS-CoV-2 infections. This approach could significantly reduce the number of severe cases and mortality rates.

Research indicates that NK cell-based immunotherapy strategies may be crucial for the early treatment and prevention of COVID-19, reducing the burden on healthcare systems. Additionally, for those suffering from "long COVID," symptoms such as persistent cough, chest discomfort, breathing difficulties, fatigue, and general malaise can be alleviated with autologous cell immune therapy. This treatment has been shown to improve immune function and quality of life in individuals experiencing suboptimal health.

"In the 21st century, cell therapy is attempting to solve problems that traditional medicine has yet to address." Our ongoing research and clinical applications underscore the transformative potential of stem cells and NK cells in treating and preventing COVID-19 and its long-term effects.